Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes - PubMed (original) (raw)

Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes

Sabrina Oliveira et al. Int J Pharm. 2007.

Abstract

Small interfering RNA (siRNA) molecules are the functional mediators of a post-transcriptional gene silencing process known as RNA interference (RNAi). The silencing of genes involved in diseases, using siRNA, is considered a very promising therapeutic strategy. However, as for all the nucleic acid based therapeutics, these negatively charged and hydrophilic molecules do not readily cross biological membranes. The use of cationic carriers generally results in positively charged complexes which are taken up by cells through endocytosis. Still, for gene silencing, these complexes need to escape through the endosomal membrane, thereby reaching the cytosol where all the RNAi machinery is present. One of the strategies developed to facilitate endosomal escape mimics the fusion of viral envelopes with host cell endosomal membranes, which occurs during viral infections. Several synthetic fusogenic peptides have been synthesized based on the fusion domain of the influenza virus. In this study we evaluated the effects of the influenza-derived fusogenic peptide diINF-7 on gene silencing efficiency of siRNA targeting the epidermal growth factor receptor (EGFR) and the K-ras oncogenes. For both targets, strong enhancement of gene silencing activity was noted after addition of diINF-7 fusogenic peptide, identifying endosomal escape as a limiting factor for siRNA silencing efficiency.

PubMed Disclaimer

Cited by

Treating Pulmonary Fibrosis with Non-Viral Gene Therapy: From Bench to Bedside.
Huang T, Gao J, Cai L, Xie H, Wang Y, Wang Y, Zhou Q. Huang T, et al. Pharmaceutics. 2022 Apr 7;14(4):813. doi: 10.3390/pharmaceutics14040813. Pharmaceutics. 2022. PMID: 35456646 Free PMC article. Review.
Current Transport Systems and Clinical Applications for Small Interfering RNA (siRNA) Drugs.
Liu F, Wang C, Gao Y, Li X, Tian F, Zhang Y, Fu M, Li P, Wang Y, Wang F. Liu F, et al. Mol Diagn Ther. 2018 Oct;22(5):551-569. doi: 10.1007/s40291-018-0338-8. Mol Diagn Ther. 2018. PMID: 29926308 Review.
Interfering with disease: a progress report on siRNA-based therapeutics.
de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. de Fougerolles A, et al. Nat Rev Drug Discov. 2007 Jun;6(6):443-53. doi: 10.1038/nrd2310. Nat Rev Drug Discov. 2007. PMID: 17541417 Free PMC article. Review.
New short interfering RNA-based therapies for glomerulonephritis.
Shimizu H, Fujita T. Shimizu H, et al. Nat Rev Nephrol. 2011 May 24;7(7):407-15. doi: 10.1038/nrneph.2011.61. Nat Rev Nephrol. 2011. PMID: 21610682 Review.
Nanotechnology: A Promising Approach for Cancer Diagnosis, Therapeutics and Theragnosis.
Dessale M, Mengistu G, Mengist HM. Dessale M, et al. Int J Nanomedicine. 2022 Aug 26;17:3735-3749. doi: 10.2147/IJN.S378074. eCollection 2022. Int J Nanomedicine. 2022. PMID: 36051353 Free PMC article. Review.

Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes - PubMed (original) (raw)